Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-04

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Severe hypoxemia following trauma may happen in many circumstances (aspiration, ventilation-associated pneumonia, lung contusion...), most of which are not exclusively associated with a direct injury to the lungs. Severe trauma and associated musculoskeletal injuries result in the acute release of Damage-Associated Molecular Patterns (DAMPs) in plasma, many of which are made of nucleic acids. DAMPs then bind leukocytes and trigger NETosis (Neutrophil Extracellular Traps), the release of nuclear material coated with proteolytic enzymes, which ultimately promotes remote lung injury and acute respiratory distress syndrome (ARDS).

Considering that many DAMPs and all NETs are made of nucleic acids, we hypothesize that dornase alfa, a commercially available recombinant desoxyribonuclease (DNAse) could reduce DAMPs and NETs-induced lung injury in severe trauma patients under mechanical ventilation in the intensive care unit (ICU).

The primary objective is to demonstrate a reduction in the incidence of moderate to severe ARDS in severe trauma patients during the first seven ICU days from 45% to 30% by providing aerosolized dornase alfa once during the first two consecutive ICU days and compared to equivalent provision of placebo (NaCl 0,9%).

The secondary objectives are to demonstrate, by using aerosolized dornase alfa compared to placebo:

* an improvement in static lung compliance
* a reduction in mechanical ventilation duration / an increase in ventilation-free ICU days
* a reduction in the length of ICU stay
* a reduction in the hospital length of stay
* a reduction in multi-organ failure
* a reduction in ventilator-associated pneumonia (VAP)
* a reduction in mortality at day 28

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Steroids in Patients With Early ARDS

NCT00562835

Acute Lung Injury ARDS, Human

UNKNOWN PHASE2/PHASE3

Dornase Alfa and Urokinase for Kids With Pleural Empyema

NCT00502632

Pleural Empyema

UNKNOWN PHASE2/PHASE3

Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children

NCT01757899

Acute Lung Injury Acute Respiratory Distress Syndrome

WITHDRAWN PHASE2

Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome

NCT01423864

Acute Respiratory Distress Syndrome (ARDS) Multiple Organ Failure

COMPLETED PHASE2

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

NCT04468971

COVID19 ARDS

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Trauma Respiratory Distress Syndrome, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dornase alfa

Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.

Group Type EXPERIMENTAL

Dornase Alfa Inhalant Solution [Pulmozyme]

Intervention Type DRUG

Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.

Placebo

NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.

Group Type PLACEBO_COMPARATOR

Placebos

Intervention Type DRUG

NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dornase Alfa Inhalant Solution [Pulmozyme]

Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.

Intervention Type DRUG

Placebos

NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (\>18) patient of either sex affiliated to the National Health Service

* Severe trauma patient (either blunt or penetrating), Injury Severity Score \> 15
* Under mechanical ventilation for an expected duration \> 48h
* Admitted in the ICU
* Signed informed consent from the patient's relative
* Patient equipped with an indwelling arterial catheter

Exclusion Criteria

* Pregnancy or breast feeding

* Opposition from the patient or his/her relatives
* Protected major (Guardianship)
* Contraindication to the use of dornase alfa
* Known intolerance to dornase alfa

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No